FRACTYL HEALTH ($GUTS) posted quarterly earnings results for Q4 2025 on Tuesday, March 24th. The company reported earnings of $0.15 per share, beating estimates of -$0.18 by $0.33. The company also reported revenue of $0, equaling estimates of $0 by $0.
You can see Quiver Quantitative's $GUTS stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
FRACTYL HEALTH Insider Trading Activity
FRACTYL HEALTH insiders have traded $GUTS stock on the open market 1 times in the past 6 months. Of those trades, 1 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $GUTS stock by insiders over the last 6 months:
- HARITH RAJAGOPALAN (Chief Executive Officer) purchased 10,416 shares for an estimated $19,998
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
FRACTYL HEALTH Hedge Fund Activity
We have seen 64 institutional investors add shares of FRACTYL HEALTH stock to their portfolio, and 42 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- ROSALIND ADVISORS, INC. removed 4,614,269 shares (-92.3%) from their portfolio in Q4 2025, for an estimated $10,151,391
- MARSHALL WACE, LLP added 4,156,969 shares (+234.9%) to their portfolio in Q4 2025, for an estimated $9,145,331
- VANGUARD GROUP INC added 4,107,032 shares (+213.8%) to their portfolio in Q4 2025, for an estimated $9,035,470
- PALE FIRE CAPITAL SE added 3,209,942 shares (+inf%) to their portfolio in Q4 2025, for an estimated $7,061,872
- GOLDMAN SACHS GROUP INC added 2,934,749 shares (+598.4%) to their portfolio in Q4 2025, for an estimated $6,456,447
- SOLEUS CAPITAL MANAGEMENT, L.P. removed 2,100,000 shares (-84.0%) from their portfolio in Q4 2025, for an estimated $4,620,000
- ATOM INVESTORS LP added 1,883,018 shares (+inf%) to their portfolio in Q4 2025, for an estimated $4,142,639
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
FRACTYL HEALTH Analyst Ratings
Wall Street analysts have issued reports on $GUTS in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Canaccord Genuity issued a "Buy" rating on 11/21/2025
- HC Wainwright & Co. issued a "Buy" rating on 09/26/2025
To track analyst ratings and price targets for FRACTYL HEALTH, check out Quiver Quantitative's $GUTS forecast page.
FRACTYL HEALTH Price Targets
Multiple analysts have issued price targets for $GUTS recently. We have seen 3 analysts offer price targets for $GUTS in the last 6 months, with a median target of $8.0.
Here are some recent targets:
- Michael Ulz from Morgan Stanley set a target price of $2.0 on 01/30/2026
- Joseph Pantginis from HC Wainwright & Co. set a target price of $8.0 on 12/02/2025
- Whitney Ijem from Canaccord Genuity set a target price of $8.0 on 11/21/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
